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Abstract
Temporins are antimicrobial peptides secreted by the granular glands of the European red frog (Rana temporaria). They are
10–14 amino acid long polypeptides active prevalently against gram positive bacteria. This study shows that a synthetic
temporin B analogue (TB-YK), acquires the capacity to act in synergism with temporin A and to exert antimicrobial and anti-
inflammatory activity in vivo against gram positive and gram negative bacteria. Administration of 3.4 mg/Kg of temporin A
(TA)+1.6 mg/Kg TB-YK, given to individual mice concurrently with a lethal dose of bacteria (gram positive or negative),
rescued 100% of the animals. More importantly, the same doses of temporins, administered one week after experimental
infection with a sub lethal dose of bacteria, sterilized 100% of the animals within 3–6 days. Also, it is described an animal
model based on the use of sub lethal doses of bacteria, which closely mimics bacterial infection in humans. The model
offers the possibility to test in a preclinical setting the true potential of TA and TB-YK in combination as antimicrobial and
anti-inflammatory agents.
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Introduction
Antimicrobial peptides (AMP) are essential components of the
innate immune system of plants and animals, including humans
[1]. AMPs, though highly different in size and secondary structure,
display important common characteristics, such as a net positive
charge at neutral pH, the ability to interact with the bacterial
membrane and kill a large spectrum of bacteria [2]. The
worldwide phenomenon of bacterial resistance to conventional
antibiotics has made urgent the search for antibacterial drugs
active against antibiotic-resistant bacteria [3]. AMPs are among
the most promising candidates, in view of their small size (which
simplifies their chemical synthesis), a large spectrum of activity
against gram positive and gram negative bacteria, and limited
toxicity towards eukaryotic cells [4,5]. In particular, temporins are
AMPs produced and secreted by the granular glands of the
European red frog (Rana temporaria) [6,7]. They are amphipathic a-
helical polypeptides, 10–14 amino acid long, containing only 1 or
2 positively charged amino acids (R or K). These peptides are
amidated at the C-terminus as a result of an enzymatic post-
translational reaction [8]. Temporins are active prevalently against
gram positive bacteria, including methicilline and vancomycine-
resistant staphilococci and enterococchi, and are non toxic on
mammalian cells. Temporin L, which contains an arginine and a
lysine residue in the sequence, is the only member of the family
which exhibits antibacterial activity against both gram positive and
negative bacteria [9]. Interestingly temporins A and B, in
combination with Temporin L, show anti-bacterial activity against
Gram negative bacteria [10]. The mechanism of action of
temporins has not entirely been clarified; it has been shown that
the sequence, the charge distribution, the secondary structure all
influence the ability of the peptides to interact with bacterial
membranes; cationic AMPs preferentially interact with the
negatively charged bacterial membranes by altering the mem-
brane permeability [11,12]. In Gram negative bacteria the
microbial wall is surrounded by the lipopolysaccharide layer
(LPS), which represents a further hurdle for the peptides before the
cytoplasmic membrane. It has been demonstrated that Temporins
A and B oligomerize when they reach the LPS, suggesting that the
inactivity of these peptides towards Gram negative bacteria may
be due to the oligomerization process which in turn hampers the
peptide uptake [10]. In contrast, Temporin L disaggregates when
in contact with the LPS; furthermore it is also able to inhibit
oligomerization of temporin A and B, allowing for the transloca-
tion of these peptides in the Gram negative inner membrane. Data
recently reported on AMPs derived from a combinatorial library
suggest that the antimicrobial activity of AMP is related to the
ability of the peptide to destabilize membranes by partitioning into
membrane interfaces and disturbing the organization of the lipids
[13].
Few analogues of temporins have been investigated so far [14–
17]. Dimeric Temporin A was shown to have antimicrobial
activity also towards both the Gram negative bacteria E.coli, unlike
the wt Temporin A [16]. The temporin A P3N analogue exhibits
improved ability to lyse human red blood cells as compared to wt
Temporin A and an improved antimicrobial activity especially
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against Gram-positive bacterial strains and Candida [15]. In vitro
experiments showed that the D isomer of Temporin B is active
against several anaeorobic bacteria and is also stable in the fecal
milieu, suggesting it can be employed for the treatment of the
Clostridium difficile. [17] The effect of Temporin A was also
studied in vivo in a mouse model of Staphylococcus sepsis; it was
found that the peptide reduces the lethality rates and bacterial
growth, the antibacterial activity is enhanced when Temporin A
was used in combination a with the antibiotic Imipenem [18].
The present article demonstrated by in vitro and in vivo
experiments that synthetic temporin A (in its native form) and a
temporin B analogue act synergistically against the majority of
gram positive and gram negative bacteria tested. Notably, the
combination of the two temporins is active against methicillin-
resistant strains of S. aureus.
Materials and Methods
Synthesis of antimicrobial peptides
The amino acids used for the peptide synthesis, Fmoc-b-Ala-
OH, Fmoc-Arg(Pbf)-OH, Fmoc-Asn(Trt)-OH, Fmoc-Gly-OH,
Fmoc-Ile-OH, Fmoc-Leu-OH, Fmoc-Ser(OtBu)-OH, Fmoc-Phe-
OH, Fmoc-Pro-OH, Fmoc-Val-OH, Fmoc-Tyr(OtBu)-OH -, the
Rink amide MBHA and the activators N-Hydroxybenzotriazole
(HOBT) and O-Benzotriazole-N,N,N’,N’-tetramethyl-uronium-
hexafluoro-phosphate (HBTU) were from Novabiochem (Gibbs-
town, NJ, USA). Acetonitrile (ACN) was from Reidel-deHae¨n
(Seelze, Germany) and dry N,N-dimethylformamide (DMF) from
LabScan (Dublin, Ireland). All other reagents were from Fluka
(Milan, Italy). LC-MS analyses were performed on a LC-MS
Thermo Finnigan with an electrospray source (MSQ) on a
Phenomenex Jupiter 5 m C18 300 A˚, (15064.6 mm) column.
Purification was carried out on a Phenomenex Jupiter 10 m Proteo
90 A˚ (250610 mm) column. Peptides were synthesized on a Rink-
amide 4-methyl benzhydrylamine (MBHA) resin (0.63 mmol/g)
using repetitive cycles of coupling, capping and deprotection.
Amino acids (10 eq.) were preactivated for 5 min in the presence
of a 0.5 M hydroxybenzotriazole (HOBT) and O-benzotriazole-
N,N,N,N,-tetramethyl-uronium-hexafluoro-phosphate (HBTU)
(9.8 eq) in dimethylformamide (DMF) solution and N,N-
diisopropylethylamine (DIPEA) (30 eq) and coupled for 60
minutes. The resin was washed with DMF (two flow washes,
25 s each). Capping was performed with a solution of acetic
anhydride/DIPEA/DMF (15/15/70 v/v/v) for 5 min, followed
by two flow washes (25 s each) with DMF. Deprotection was
performed with a solution of piperidine in DMF (20/80; v/v) for
seven minutes. The resin was washed with DMF (two flow washes
of 25 s each). At the end of the synthesis, the resin was washed
with dichloromethane and dried in vacuum. The peptides were
cleaved off the resin and deprotected by a treatment with a
solution of trifluoroacetic acid (TFA)/triisopropyl silane (TIS)/
H2O (90/5/5) (90 minutes at room temperature). Peptides were
purified using the following gradient: isochratic 30% water
containing 0.1% TFA (5 min), followed by a gradient of 30–
80% acetonitrile in water containing 0.1% TFA (30 min).
Lyophilized peptides were dissolved in H2O/CH3COOH (1/1;
v/v) and lyophilized again. All peptides were characterized by
electrospray mass analysis.
Peptide labelling
Reactions with fluorophores were carried out on peptides still
anchored to the resin. Two b alanines (bA) were added at the N-
terminus of TB-YK and TA before labelling. [19] Fluorescein
isothiocyanate or rhodamine isothiocyanate (10 eq; Sigma-
Aldrich, Milan, Italy) were dissolved in the minimum volume of
dry DMF containing DIPEA (30 eq) and incubated for 2 hours at
room temperature in the dark with the resin bound peptides. The
resin was then washed with DMF, and the peptide cleaved off the
resin, deprotected and purified as described above.
Circular dichroism
Circular dichroism (CD) spectra were recorded on a Jasco J-715
spectropolarimeter, equipped with a Jasco Peltier PTC-423S/15,
using a 1 cm quartz cell. Spectra were recorded in 10 mM sodium
phosphate buffer pH 7.4 and in 10 mM sodium phosphate,
20 mM sodium dodecyl sulphate (SDS) buffer pH 7.4 at 25uC.
Peptides concentration was 5 mM. Spectra were obtained as an
average of eight scans, acquired in the range 320–195 nm. All
spectra are reported in molar ellipticitiy per residue (mre) vs
wavelenght (nm).
Bacteria
The study included the following species: Staphylococcus aureus
(isolate A170, A172, 007), Listeria monocytogenes, Salmonella enterica
serovar Paratyphi, Salmonella enterica serovar Typhimurium, Esche-
richia coli. Isolates were obtained from patients hospitalized at the
Medical School of the University of Naples. Specimen were
confirmed by PCR assay of the genes sea (S. aureus), MonoA (L.
monocytogenes), abe (S. enterica serovar Paratyphi), FliC (S. enterica
serovar Typhimurium), sat (E. coli) [20–23]. Bacteria were grown at
37uC in TSB medium (S. aureus and L. monocytogenes) or LB medium
(the remaining bacterial species) (Difco, Becton Dickinson, Sparks,
MD), harvested while in exponential phase (OD600 nm; 0-6-0.8),
centrifuged (86103 g for 10 min), washed with saline (0.15 M
NaCl) and resuspended in saline (106–107 CFU/ml).
S. enterica transformation. The green fluorescent protein
(GFP) gene was cloned into the HindIII-PstI sites of the pUC19
plasmid. The plasmid was then introduced into S. enterica serovar
Paratyphi B (isolate 0404572) by electroporation as described [24].
Briefly, bacteria were grown to mid-log phase in LB broth, washed
with 10% glycerol in double distilled H2O, suspended at
1012 cells/ml and mixed with 1 mg of DNA. An aliquot (40 ml)
was pulsed at 1.75 kV/cm, 800 V, and 25 mF. Following
electroporation, the transformed bacteria were incubated for
30 min at 37uC in 1 ml LB broth supplemented with 0.3 M
sucrose. Bacteria were then spread on LB agar plates containing
100 mg/ml ampicillin (Sigma-Aldrich, Milan, Italy).
Mice
Experiments were carried out on females BALB/c mice (aged
8–10 weeks) at the animal facility of the University of Naples.
Untreated mice were infected intravenously with bacteria (S.
aureus: 107 CFU/mouse and S. enterica serovar paratyphi:
106 CFU/mouse). Treated mice were infected (as just described)
and immediately after were given intravenously the antimicrobial
peptide combination (3.4 mg/Kg TA+1.6 mg/Kg TB-YK in
saline (0.15 M NaCl). One gram of infected organs - the kidneys
in the case of infection with S aureus; liver and gastro intestinal (GI)
tract in the case of infection with remaining bacteria - was
homogenised in 1 ml saline and serially diluted in saline. CFU
were evaluated by plating each dilution on Baird Parker agar (to
detect the S aureus) or XLT-4 agar (to detect the remaining
bacteria). Plates were incubated overnight at 37uC.
Antibacterial activity
Bacteria were grown at 37uC in TSB (S. aureus and L.
monocytogenes) or in LB medium (the remaining bacterial species),
Antimicrobial Peptides
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harvested while in exponential phase (OD600 nm; 0-6-0.8),
centrifuged (86103 g for 10 min), washed with saline, resuspended
in Muller Hinton (MH) broth at the concentration of approxi-
mately 106 CFU/ml and distributed, in triplicate, into 96 well
plates (60 ml/well), mixed with twofold dilutions of the antimicro-
bial (TA: 5–100 mg, 40 ml/well; TB-YK: 4–100 mg, 40 ml/well;
TA 5 mg+TB-YK 8 mg, 40 ml/well and incubated at 37uC for
20 h. The minimal concentration of the antimicrobial at which
100% inhibition of growth was observed (MIC100) was determined
by measuring the absorbance at 600 nm (Biorad microplate reader
model 680, Hercules, CA). The antibacterial activity was
measured by spotting an aliquot (10 ml) of each well on TSA or
LB agar and counting the CFU. A potential synergism between
temporins was evaluated by adding combinations of two temporins
in a serial twofold dilutions (TA: 5–100 mg;TB-YK: 4–100 mg;
40 ml/well) to wells containing 105 CFU/well in 60 ml. The
presence of synergism was established as described [10].
Inhibition zone assay
Bacteria were grown as described above, suspended in LB
(26105 CFU/ml), mixed with 3 ml of 0.7% soft agar (Sigma) and
poured on Petri dishes containing 10 ml LB agar. Serial dilutions
of the antimicrobial (TA and TB-YK) alone or in combination)
were deposited into holes (10 ml/well) made into the agarose bed.
Plates were then incubated at 30uC for 12 h.
Electron microscopy
Bacteria (S. aureus or S. enterica serovar Paratyphi; 106 CFU/
60 ml) were mixed on a microscope slide with the antimicrobial
combination (S. aureus: 5 mg TA+8 mg TB-YK in a total volume of
40 ml; S. enterica serovar Paratyphi: 100 mg TA+4 mg TB-YK in a
total volume of 40 ml), incubated overnight in 2.5% gluteraldehyde
and then treated for 1 h, in succession, with 20%, 40%, 60%
ethanol and overnight with 70% ethanol. The slides were finally
washed with 90% and 100% ethanol for 1 h, dried at 37uC for
15 min and observed with the SEM Zeiss microscope (Evo 40,
Jena, Germany).
Test of the haemolytic activity of the antimicrobials
The temporins were tested individually for their haemolytic
activity using mouse red blood cells. The blood was collected from
the tail of the animals and centrifuged (46102 g for 3 min). The
erythrocytes were washed with saline, suspended at 36106 eryth-
rocytes/ml, mixed with the peptide combination (75 mg TA+35 mg
TB-YK in 100 ml saline) and incubated for 1 h at 37uC. The
haemolytic activity was measured according to the formula OD
peptide - OD negative control/OD positive control - OD negative control
6100 where the negative control (0% haemolysis) was represented
by erythrocytes suspended in saline and the positive control (100%
haemolysis) was represented by the erythrocytes lysed with 1%
triton X100 [25].
Real time PCR of pro-inflammatory cytokines
Two groups of mice (4 mice/group) were infected intravenously
with S. enterica serovar Paratyphi. One group of mice was used as
untreated control, while the second group was injected intrave-
nously with the antimicrobial (3.4 mg/Kg TA+1.6 mg/Kg TB-YK;
75 mg TA+35 mg TB-YK n 100 mL in saline) immediately after
infection. Total RNA was isolated from mouse liver at 3, 6, 24 and
48 h after treatment by using Trizol reagent (Invitrogen, Milan,
Italy). RNA was suspended in RNase-DNAse free distilled water,
assessed for concentration (by measuring the absorbance at 260 nm)
and purity (by ascertaining that the A260/A280 ratio was .1.9).
RNA (1 mg) was then treated with 1U RNAse-free DNAse
(Promega, Madison, WI). DNA contamination of RNA samples
was excluded by PCR with primers specific for the gapdh gene.
Reverse transcription was carried out with ImProm-II reverse
transcriptase (Promega, Madison, WI) and oligo(dT)18. Real-time
PCR was performed on 50 ng cDNA, using 1x master mix SYBR-
Green (Applied Biosystem, Milan) in a StepOne Applied Biosystem
instrument (Applied Biosystem, Milan). Reactions were performed
in 20 ml in triplicate with the following thermal profile: 95uC for
10 min and 45 cycles of 15 s at 95uC and 45 s at 60uC;1 min at
60uC; 15 s at 95uC plus 0.3uC at each step of the melting curve.
PCR primers (0.2 mM each) were as follows: GAPDH forward, 59
TTCACCACCATGGAGAAGGC 39; GAPDH reverse, 59 GGC-
ATGGACT GTGGTCATGA 39; IL-6 forward, 59 AAAGAGT-
TGTGCA ATGGCAATT 39; IL-6 reverse, 59 CAGTTTGGT-
AGCATCCATCAT 39; TNF-a forward, 59 TCTCAGCCT-
CTTCTC ATTCCT39 ; TNF-a reverse, 59 GTCTGGGCCATA-
GAACTGATG 39; IL-4 forward, 59AATGTACCAGGAG CCA-
TATCCAC 39; IL-4 reverse, 59 TCACTCTCTGTGGTGTT
CTTCGT 39; IFN˜c forward, 59 AGCGGCTGACTGAACTCA-
GATTGTAG 39; IFN-c reverse, 59 GTCACAG TTTTCAGCTG
TATAGGG 39.
Other methods
Leukocytes formula and haemachrome of mice were deter-
mined with the Am45 instrument (Melet Schloesing, Osny,
France). Mice infected with GFP-labelled bacteria were analysed
using the Leica macrofluo instrument (Wetzlar, Germany)
equipped with the Leica application suite 3.1.0 software.
Survival rates of mice were analyzed using Fisher’s exact test.
Bacterial counts and cytokines levels were analyzed using
Student’s t test.
Results
Synthesis and circular dichroism characterization of the
peptides
Antimicrobial peptides were synthesised by standard solid
phase technique and characterized by LC-MS. Analysis of the
temporin B structure suggested some modifications that poten-
tially might have improved its use. First, one extra tyrosine
residue was added to the N- terminus of the temporin B. This
modification conferred to the peptide a distinctive absorption
pattern at 280 nm. The concentration of the peptide could thus
be measured precisely. Second, studies of the interaction between
the temporin B and biomembrane models have shown that
temporin B forms a complex with the acidic phospholipid
component of the membrane [26]. The addition of two extra
positive charged lysine residues to the N-terminus of the
temporin B, to give TB-YK, was therefore thought to facilitate
the electrostatic interaction with the negatively charged phos-
pholipids. For the in vivo studies peptides need to be labelled with
fluorescent dyes; we obtained temporin A derivatized with
rhodamine (TA-Rho) and Temporin B derivatized with a
fluoresceine (TB-Fluo). Before labelling, to prevent degradation
of the peptide, two b alanines (bA) were added at the N-terminus
of temporins [19]. The secondary structure of TB and TB-YKbA
analogue was studied by CD in phosphate buffer and phosphate
buffer plus SDS. CD spectra of the peptides in sodium phosphate
buffer pH 7.4 showed a minimum close to 200 nm, indicative of
a random coil conformation. In contrast, in SDS both peptides
assumed an a helical conformation, as suggested by the minima
around 209 and 222 nm (Figure 1).
Antimicrobial Peptides
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In vitro experiments
The study examined the antimicrobial activity of the synthetic
temporins A and B in their native forms, and of the temporin B
following chemical modifications (Table 1); the latter temporin was
studied alone and in combination with native temporin A. The
native temporin A was more active against gram positive (MIC:
10–30 mg/ml) than against gram negative (MIC: 125–400 mg/ml)
bacteria (Table 2); the native temporin B and TB-Y were active
against gram positive bacteria (approximately to the same extent
as temporin A), but totally inactive against gram negative bacteria
(data not shown). Also, tested in different ratios, the two native
temporins did not display synergism. Instead TB-YK exhibited
antimicrobial activity either against gram positive and gram
negative bacteria (Table 2). Remarkably, when modified TB-YK
(at 4–8 mg/ml) was used in combination with the native temporin
A (at 5–100 mg/ml), a strong synergism was observed against gram
positive as well as against gram positive bacteria (Table 2).
Electron microscopy showed the ability of the combination of TA
and TB-YK to perforate the bacterial membrane (Figure 2). The
labelled peptides, TA-Rho and TB-Fluo, were employed in
fluorescence light microscopy experiments. Several combinations
of the peptides were tested; the combinations which allowed for a
better visualization of the bacteria were 6 mg TA+9 mg TB-YK on
S.aureus 170 and 15 mg TA+20 mg TB-YK on S.enterica Paratyphi.
The end product of temporins’ activity, bacterial fragmentation, is
illustrated in Figure 3. An independent experimental approach,
the inhibition zone test, confirmed the synergism between the two
temporins (Figure 4).
In vivo experiments
On the basis of the results described above, the therapeutic
potential of the TA in combination with TB-YK was tested in a
mouse model. The test, if successful, offered the possibility to assess
the potential clinical use of the two temporins against septic shock
caused by gram positive or gram negative bacteria. Several
combinations of the two temporins displayed the capacity to
protect mice from lethal doses of bacteria. Among these, the
combination of 3.4 mg/Kg TA 0.54 mM in saline +1.6 mg/Kg
TB-YK 0.19 mM in saline/mouse (75 mg TA+35 mg TB in 100 ml
saline) was chosen for further studies because provided the highest
surviving rate of mice infected with gram positive and gram
negative bacteria and did not display haemolytic activity. This
temporin combination, used in all the experiments to be described,
will be referred to as the 75/35 pool. Two groups of mice (24
animals/group; untreated groups) were infected intravenously with
S. enterica serovar Paratyphi (106 CFU/mouse) or S. aureus A170
(107 CFU/mouse), respectively. Two more groups of mice (24
animals/group; treated groups) were infected by the same
procedure and, immediately after, treated with the 35/75 pool.
Untreated mice died all within 4–6 days. The treated mice were all
alive 28 days after the temporin treatment. (Figure 5). In an
independent experiment, 2 mice infected as described (untreated
mice) and 2 mice infected and then treated as above (treated mice)
were sacrificed at daily intervals to monitor the bacterial load in
the target organs (liver and GI tract of mice infected with S. enterica
serovar Paratyphi; the kidneys of mice infected with S. aureus).
Treated mice cleared S aureus or S. enterica serovar Paratyphi within
3 (Figure 6A) or 6 Figure 6B–C days from temporin treatment,
respectively. Untreated mice, instead, remained heavily infected
till the time of death (Figure 6A–C). The results demonstrated the
efficacy of the 35/75 pool in vivo. Remarkably, the 35/75 pool
was active against the methicillin-resistant S. aureus A170 strain.
Efficacy of delayed treatment with the 35/75 pool
Typically, bacterial infections are caused by a small initial
inoculum. Therefore, to be clinically useful, temporins must be
effective when started several days after infection. To see whether
the 35/75 pool displayed this potential, mice were infected with a
sub-lethal dose of bacteria (105 CFU/mouse) and one week later
treated with the 35/75 pool. The 105 CFU/mouse dose was the
inoculum that the innate immune system of the animal could not
rapidly control. Again, the pool was effective in sterilizing the
animals within 5 days (Figure 7).
The peptide pool protects from inflammation
Mice infected with S. enterica serovar Typhimurium (106 CFU/
mouse; untreated mice), 24 hours after infection displayed enlarged
spleen, liver, and mesenteric lymph nodes because of inflammation,
while mice infected with the same pathogen and immediately after
treated with the 35/75 pool (treated mice) displayed only minor
morphological changes in the organs. Untreated mice displayed also
significant changes of the following parameters, indicative of a
systemic immune response to infection: reduced number of red
blood cells and leukocytes, reduced haemoglobin concentration and
Table 1. Amino acid sequence and molecular mass of the
temporins used in the study.
Peptide Amino acid sequence Molecular mass
Calculated Found
TA H-FLPLIGRVLSGIL-NH2 1396,7 1396,3
TB H-LLPI VGNLLKSLL- NH2 1391.8 1391.2
TB-Y H-YLLPI VGNLLKSLL- NH2 1554.9 1554.7
TB-YK KKYLLPIVGNLLKSLL- NH2 1811,3 1812,8
TB-YKbA H2bAbA KKYLLPI VGNLLKSLL- NH2
(bA= bAla)
1953,4 1953,7
TA Rho Rho-bAbA KK FLPLIGRVLSGIL-NH2
(bA= bAla)
2295,4 2294,3
TB Fluo Fluo-bAbA KK YLLPI VGNLLKSLL- NH2
(bA= bAla)
2342,8 2343,2
doi:10.1371/journal.pone.0007191.t001
Figure 1. CD spectra of: TB (blue, continuous line), TB-YKbA
(red continuous line) in Sodium Phosphate buffer pH 7.4 (-); TB
(blue dashed line) and TB-YKbA (red dashed line) in Sodium-
Phosphate buffer+SDS pH 7.4.
doi:10.1371/journal.pone.0007191.g001
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red blood cell volume, (Table 3). Elevated body temperature and
elevated levels of circulating lipopolysaccharide (LPS)-binding
protein and serum amiloid A (data not shown) characterized the
untreated (but not the treated) mice.
Treated mice, compared to the untreated ones, showed lower
levels of the pro-inflammatory cytokines TNF-a and INF-c and
higher levels of the anti-inflammatory cytokines IL-4 and IL-6,
indicative of a more balanced Th1/Th2 response (Figure 8). To
Table 2.
Bacterial species/strains MIC FIC indexa
Gram+ TA TB-YK TA+TB-YK
Staphilococcus.aureus A170 10 mg/ml 20 mg/ml 5 mg/ml+8 mg/ml 0,5
Staphilococcus .aureus A172 20 mg/ml 25 mg/ml 8 mg/ml+5 mg/ml 0,5
Staphilococcus aureus 007 10 mg/ml 10 mg/ml 8 mg/ml+3 mg/ml 1,1
Listeria monocytogenes 30 mg/ml 10 mg/ml 10 mg/ml+3 mg/ml 0,6
Gram2
Salmonella enterica serovar Paratyphi 400 mg/ml 20 mg/ml 100 mg/ml+4 mg/ml 0,4
Escherichian coli 125 mg/ml 20 mg/ml 50 mg/ml+5 mg/ml 0,6
aThe FIC indices were interpreted as follows: #0.5, synergy; .0.5, no interaction.
doi:10.1371/journal.pone.0007191.t002
Figure 2. Temporins initiate their antibacterial activity by drillings holes in the bacterial membrane. A: S.aureus A170, untreated; B: S
aureus A 170 treated for 10 min with TA (8 mg/ml) plus TB-YK (5 mg/ml) (B); C: S.enterica serovar Paratyphi B untreated; D: S.enterica serovar Paratyphi
B treated for 10 min with TA (100 mg/ml) plusTB-YK (4 mg/ml).
doi:10.1371/journal.pone.0007191.g002
Antimicrobial Peptides
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study the anti-inflammatory activity of temporins under conditions
that more closely reproduce bacterial infection in humans, the
experiment was repeated using a small initial inoculum of bacteria.
Mice were infected with S. enterica serovar Typhimurium
(105 CFU/mouse) and 6 days later treated with the 35/75 pool.
The cytokine expression levels in the liver were monitored daily by
RT-PCR. The experiment demonstrated that temporins bring the
levels of the cytokines back to those of naı¨ve mice within 5 days
(Figure 9). The experiments on cytokines as described in this
paragraph were repeated on mice infected with S. aureus and
yielded very similar results.
Mice were infected with a sub-lethal dose of Salmonella GFP
106 CFU/mouse and immediately treated with the 35/75 pool.
24 hours later, the animals were sacrificed and intestine and liver
were extracted. Observation of the organs at the Macrofluo
microscope revealed a reduction in the fluorescence of the treated
mice, as compared to untreated mice, which further confirms the
efficacy of the pool 35/75. (Figure 10)
Discussion
The antimicrobial activity of temporin A and a temporin B
analogue has been investigated in vitro and in vivo. Results
reported here highlight how small alterations of the native
Figure 3. Detection of total, viable and membrane-perturbed bacteria using temporin A or temporin B labeled with rhodamine
isothiocyanate or fluorescein isothiocyanate respectively. A- B-C: S.aureus A 170 plus TA-Rho 6 mg plus TB-Fluo 9 mg; D-E-F: S.aureus A170
plus fluorescein isothiocyanate o rhodamine isothiocyanate (control); G-H-I: S.enterica serovar Paratyphi B plus TA-Rho 15 mg plus TB-Fluo 20 mg; L-M-
N: S.enterica serovar Paratyphi B plus fluorescein isothiocyanate o rhodamine isothiocyanate (control).
doi:10.1371/journal.pone.0007191.g003
Figure 4. Synergism between TA and TB-YK temporins. The
diameter of the inibition was maesured after 24 h incubation.
doi:10.1371/journal.pone.0007191.g004
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temporin B primary structure can influence dramatically its
properties. Addition of two extra positive charged lysine residues at
the N-terminus conferred to the analogue (TB-YK) a strong
synergism with the native temporin A (Table 2).
In order to get details on the secondary structure of the peptides
and to demonstrate that addition of the bAbAKK tail in the
fluorescent derivatives does not influence the secondary structure of
the peptides, CD analysis was carried out on TB and TB-YKbA in
sodium phosphate buffer pH 7.4 and in sodium phosphate plus
sodium dodecyl sulfate (SDS) buffer pH 7.4. The SDS is widely
used to mimic the negatively charged bacterial membrane. The CD
spectra obtained show that TB and TB-YKbA do not have a
defined secondary structure in the absence of SDS, while they
assume an a helical conformation in SDS. These results suggest
that: a) addition of the sequence bAbA KK at the N-terminus of TB
does not alter the secondary structure of the peptide and b) both TB
and TB-YKbA assume a defined secondary structure when interact
with membranes. Furthermore, a comparison of the CD spectra of
temporin B described here and temporin A reported in the literature
indicates that the peptides have both the same conformation [15].
Alterations of the bacterial membrane for Gram positive and
Gram negative bacteria and the effects on vitality and morphology
of cells were investigated by electron microscopy and fluorescence
light microscopy. Treatment of both S. aureus A170 (Figure 2A–B)
and S. enterica serovar Paratyphi B (Figure 2C–D) with combina-
tions of TA and TB-YK results in severe perturbation of the
membrane, as demonstrated by Figure 2 in which holes in the
membranes are clearly visible. Analogous results are obtained
visualizing the bacterial membrane by fluorescent light microscopy
after treatment of the S.aureus A170 and S. enterica serovar
Paratyphi B with combinations of TA-Rho and TBFluo.
(Figure 3). When the same bacteria are treated with the fluorescent
dyes (Rhodamine and fluoresceine), no damage is evident.
The inhibition zone assay confirms that the combination of TA
and TB-YK is more potent than the single peptides: the inhibition
diameter of the bacterial growth on the plate is wider when the TA
and TB-YK are pooled than when peptide each is tested.
Studies of the haemolytic activity of various TA/TB-YK
combinations carried out on mouse red blood cells revealed that
the pool 35/75 had no haemolytic effect, unlike the wt TA and TB
and other temporins [27,28].
The 35/75 pool, given concurrently with a lethal dose of
bacteria (gram positive or negative), rescued 100% of the animals
(Figure 5). More importantly, the same pool, administered one
week after experimental infection with a sublethal dose of bacteria,
sterilized 100% of the animals within 3–6 days (Figure 6).
Figure 5. In vivo antibacterial activity of temporins. The 35/75 pool of temporins, given concurrently with bacteria, rescue 100% of mice
infected with a lethal dose of S. aureus A170 107 CFU/mouse (A: mice infected with S.aureus A170 and immediately treated with TA plusTB-YK (closed
box) and mice infected with S.aureus A170 (open triangle) or a lethal dose of S. enterica serovar Paratyphi 106 CFU/mouse (B: Mice infected with
S.enterica serovar Paratyphi B and immediately treated with TA plus TB-YK (closed box) and mice infected with S.enterica serovar Paratyphi B (open
triangle)
doi:10.1371/journal.pone.0007191.g005
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Sterilization was attained in the blood and the target organs (liver
and GI tract in the case of infection with S. enterica serovar
Paratyphi; the kidneys in the case of infection with S aureus) without
bacterial rebound. In none of the experiments did the 35/75 pool
cause adverse effects due to rapid lysis of bacteria. These results
were observed in the case of infection with gram positive (S aureus)
or gram negative (S enterica serovar Paratyphi) pathogens. The
general significance of these data invites an objective assessment of
A and B temporins as antimicrobials.
Temporins displayed also a remarkable anti-inflammatory
activity in vivo. Sepsis, an overzealous inflammatory response to
infection, is increasingly common and frequently lethal. In the USA
the incidence of sepsis is 240 per 100 000 population and the fa-
tality rates range from 25% to 70%, depending on severity and
Figure 6. Temporins sterilize mice sperimentally infected with
S aureus A170 or S.enterica serovar Paratyphi B. The 35/75 pool of
temporins, given concurrently with bacteria, sterilize mice infected with
a lethal dose (107 CFU/mouse) of S.aureus A170 (A: kidneys from mice
infected with S. aureus A170 (closed rhomb) and kidneys from mice
infected with S.aureus A170 and immediately after treated with TA plus
TB-YK (open box), or a lethal dose (106 CFU/mouse) of S.enterica serovar
Paratyphi B (B: gastro instestinal tract from mice infected with S.enterica
serovar Paratyphi B (closed rhomb) and gastro intestinal tract from mice
infected with S.enterica serovar Paratyphi B and immediately treated
with TA plus TB-YK (open box); (C: liver from mice infected with
S.enterica serovar Paratyphi B (closed rhomb) and liver from mice
infected with S.enterica serovar Paratyphi B and immediately treated
with TA plus TB-YK (open box).
doi:10.1371/journal.pone.0007191.g006
Figure 7. Temporins are effective in vivo when given 7 days
after experimental infection. Mice were infected with a sub-lethal
dose (105 CFU/mouse) of S.aureus A170 (A) or a sub-lethal dose
(105 CFU/mouse) of S.enterica serovar Paratyphi B (B–C) and 6 days later
were treated with the 35/75 pool of temporins. A: kidneys from mice
infected with S.aureus A170 (closed box) and kidneys from mice
infected with S.aureus A170 and treated after 6 days with TA plus TB-YK
(open rhomb); B: gastro instestinal tract from mice infected with
S.enterica serovar Paratyphi B (closed box ) and gastro intestinal tract
from mice infected with S.enterica serovar Paratyphi B and treated after
6 days with TA plus TB-YK (open rhomb); C: liver frommice infected with
S.enterica serovar Paratyphi B (105 CFU/mouse) (closed box) and liver
from mice infected with S.enterica serovar Paratyphi B (105 CFU/mouse)
and treated after 6 days with the TA plus TB-YK (open rhomb).
doi:10.1371/journal.pone.0007191.g007
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comorbidity [29]. Also, sepsis from gram positive bacteria has
matched that of sepsis from gram negative bacteria [30]. In this
context, the anti-inflammatory activity displayed by the 35/75 pool
represents a valuable result, especially since directed against gram
positive and gram negative bacteria. As to the mechanism leading to
the control of inflammation, it appears important the role of IL-6, a
cytokine known to control the level of pro-inflammatory cytokines
(TNF-a and INF-c) without interfering with the expression of the
anti-inflammatory cytokine IL-4 [31]. High doses of bacteria
commonly administered to experimental animals cause rapid lysis
by complement. This leads to a potential model of intoxication with
endotoxins rather than a true model of sepsis [32]. The approach
adopted in this study is exempt from this drawback since mice were
infected with a small initial bacterial inoculum.
In the course of this study, a large number of mice were infected
with different bacterial species. In no case bacterial colonies
resistant to the 35/75 pool were recovered. In vitro experiments
aimed at isolating mutants resistant to the 35/75 pool were also
Table 3. Haematological parameters of mice naive (no infected or treated), infected with S.enterica serovar Paratyphi B (106 CFU/
mouse), or infected and treated with temporin A(75 mg/mouse) plus temporin B (35 mg/mouse).
Naive Untreated Treated
Leukocytes 8,2960,56 m/mm3 1,2363,5 m/mm3 3,4360,56 m/mm3
Lymphocytes 26,662,4% 38,161,1% 51,961,8%
Monocytes 13,560,5% 12,760,4% 20,261,5%
Neutrophils 59,960,9% 40,860,6% 26,561,26%
Eosinophils 0% 8,160,5% 0,860,1%
Basophils 0% 0,360,6% 0,660,3%
Erytrocytes 11,5760,7 m/mm3 10,9361,7 m/mm3 7,6362,2 m/mm3
MCV(mean corpuscolar volume) 43,862,7 fl 46,862,2 fl 48,364,4 fl
HCT (hematocrit) 50,664,3% 51,164,2% 36,863,1%
MCH (mean concentration haemoglobin) 12,761,9 pg 12,662,5 pg 11,961,2 pg
MCHC(mean corpuscolar haemoglobin concentration 2962,1 g/dl 2763,1 g/dl 24,762,8 g/dl
RDW(widht distribution red cells) 10,462,4% 10,960,5% 19,762,2%
Hb(hemoglobin) 14,761,9 g/dl 13,861,8 g/dl 9,160,9 g/dl
Platelets 482615,2 m/mm3 611613,7 m/mm3 335619,7 m/mm3
MPV(mean volum platelets) 6,160,3 fl 5,860,9 fl 6,861,1 fl
PDW(widht distribution platelets) 7,260,6% 7,260,7% 7,261,2%
P,0,05.
doi:10.1371/journal.pone.0007191.t003
Figure 8. Expression levels of cytokine genes in mice infected with S.enterica serovar Paratyphi B (106 CFU/mouse) (In) or infected
with S.enterica serovar Paratyphi B (106 CFU/mouse) and immediately after treated with the 35/75 pool of temporins (Tr).
doi:10.1371/journal.pone.0007191.g008
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Figure 9. Expression levels of cytokine genes in mice infected with S.enterica serovar Paratyphi B (105 CFU/mouse) and 6 days lose
treated with temporins (35/75 pool). Each hystogram represents the mean value measured in 2 mice, each one tested in triplicate.
doi:10.1371/journal.pone.0007191.g009
Figure 10. Mice infected with GFP-labelled bacteria were analysed using the Leica macrofluo instrument (Wetzlar, Germany)
equipped with the Leica application suite 3.1.0 software. A: liver from mice infected with S. enterica serovar Paratyphi B; B: liver from mice
infected with S. enterica serovar Paratyphi B and immediately treated with TA plus TB-YK; C: gastro instestinal tract from mice infected with S. enterica
serovar Paratyphi B; D: gastro instestinal tract from mice infected with S. enterica serovar Paratyphi B and immediately treated with TA plus TB.
doi:10.1371/journal.pone.0007191.g010
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inconclusive. These results suggest that the bacterial membrane
(the target of temporins) is a cellular component that bacteria
cannot alter easily in order to gain resistance. This finding assumes
great value in the light of the increasing incidence of antibiotic
resistance.
In conclusion, the article provides evidence that temporin B,
following limited alterations of its primary structure, acquires the
capacity to act in synergism with temporin A and to exert
antimicrobial and anti-inflammatory activity in vivo against gram
positive and gram negative bacteria. The animal model described
closely mimics bacterial infection in humans. This model offers the
possibility to test in a preclinical setting the true potential of
temporins as antimicrobial and anti-inflammatory agents.
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